Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532

Blood

Volumn 105, Issue 4, 2005, Pages 1742-1749

  El Daly, Hesham ^b   Kull, Miriam ^b   Zimmermann, Stefan ^b   Pantic, Milena ^b   Waller, Cornelius F ^b   Martens, Uwe M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 NAPHTHALEN 2 YLBUT 2 ENOYLAMINO)BENZOIC ACID; BENZOIC ACID DERIVATIVE; BIBR 1532; CD34 ANTIGEN; PROTEIN P53; TELOMERASE; TELOMERASE INHIBITOR; TELOMERIC REPEAT BINDING FACTOR 2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL; CATALYSIS; CELL DEATH; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOSE RESPONSE; DRUG EFFECT; ENZYME STRUCTURE; FLUORESCENCE IN SITU HYBRIDIZATION; GROWTH DISORDER; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN CELL; LEUKAPHERESIS; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SHORT COURSE THERAPY; TELOMERE; TELOMERE DAMAGE; UMBILICAL CORD BLOOD;

EID: 13544268344     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-12-4322     Document Type: Article

References (43)

1. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279:349-352.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
3. Collins K. Mammalian telomeres and telomerase. Curr Opin Cell Biol. 2000;12:378-383.
4. Griffith JD, Comeau L, Rosenfield S, et al. Mammalian telomeres end in a large duplex loop. Cell. 1999;97:503-514.
5. de Lange T. Protection of mammalian telomeres. Oncogene. 2002;21:532-540.
6. van Steensel B, de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature. 1997;385:740-743.
7. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell. 1998;92:401-413.
8. Stansel RM, de Lange T, Griffith JD. T-loop assembly in vitro involves binding of TRF2 near the 3′ telomeric overhang. EMBO J. 2001;20:5532-5540.
9. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science. 1999;283:1321-1325.
10. Greider CW. Telomerase biochemistry and regulation. In: Blackburn EHG, Greider CW, ed. Telomeres. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1995:35-68.
11. Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase. Science. 1995;269:1236-1241.
12. Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997;90:785-795.
13. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003;426:194-198.
14. de Lange T. Telomere dynamics and genome instability in human cancer. In: Blackburn EHG, CW, ed. Telomeres. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1995:265-293.
15. Martens UM, Chavez EA, Poon SS, Schmoor C, Lansdorp PM. Accumulation of short telomeres in human fibroblasts prior to replicative senescence. Exp Cell Res. 2000;256:291-299.
16. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33:787-791.
17. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene. 2002;21:680-687.
18. Hodes RJ, Hathcock KS, Weng NP. Telomeres in T and B cells. Nat Rev Immunol. 2002;2:699-706.
19. Baerlocher GM, Roth A, Lansdorp PM. Telomeres in hematopoietic stem cells. Ann N Y Acad Sci. 2003;996:44-48.
20. Allsopp RC, Morin GB, DePinho R, Harley CB, Weissman IL. Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. Blood. 2003;102:517-520.
21. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell. 2002;2:257-265.
22. Mergny JL, Riou JF, Mailliet P, Teulade-Fichou MP, Gilson E. Natural and pharmacological regulation of telomerase. Nucleic Acids Res. 2002;30:839-865.
23. Tauchi T, Shin-Ya K, Sashida G. et al. Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene. 2003;22:5338-5347.
24. Asai A, Oshima Y, Yamamoto Y, et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 2003;63:3931-3939.
25. Hahn WC, Stewart SA, Brooks MW, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999;5:1164-1170.
26. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 1999;13:2388-2399.
27. Hemann MT, Strong MA, Hao LY, Greider CW. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell. 2001;107:67-77.
28. Damm K, Hemmann U, Garin-Chesa P, et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 2001;20:6958-6968.
29. Pascolo E, Wenz C, Lingner J, et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem. 2002;277:15566-15572.
30. Veelken H, Jesuiter H, Mackensen A, et al. Primary fibroblasts from human adults as target cells for ex vivo transfection and gene therapy. Hum Gene Ther. 1994;5:1203-1210.
31. Zimmermann S, Glaser S, Ketteler R, et al. Effects of telomerase modulation in human hematopoietic progenitor cells. Stem Cells. 2004;22:741-749.
32. Satyanarayana A, Greenberg RA, Schaetzlein S, et al. Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling. Mol Cell Biol. 2004;24:5459-5474.
33. Zamzami N, Marchetti P, Castedo M, et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med. 1995;181:1661-1672.
34. Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96:2655-2663.
35. Martens UM, Brass V, Sedlacek L, et al. Telomere maintenance in human B lymphocytes. Br J Haematol. 2002;119:810-818.
36. Berridge M, Tan A, McCoy K, Kansara M, Rudert F. CD95 (Fas/Apo-1)-induced apoptosis results in loss of glucose transporter function. J Immunol. 1996;156:4092-4099.
37. Martens UM, Zijlmans JM, Poon SS, et al. Short telomeres on human chromosome 17p. Nat Genet. 1998;18:76-80.
38. Blasco MA. Telomerase beyond telomeres. Nat Rev Cancer. 2002;2:627-633.
39. Taggart AK, Teng SC, Zakian VA. Est1p as a cell cycle-regulated activator of telomere-bound telomerase. Science. 2002;297:1023-1026.
40. Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells. Cell. 2003;114:241-253.
41. Cech TR. Beginning to understand the end of the chromosome. Cell. 2004;116:273-279.
42. Karlseder J, Smogorzewska A, de Lange T. Senescence induced by altered telomere state, not telomere loss. Science. 2002;295:2446-2449.
43. Nakagami Y, Ito M, Hara T, Inoue T. Loss of TRF2 by radiation-induced apoptosis in HL60 cells. Radiat Med. 2002;20:121-129.